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Abstract: Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with high
risk of relapse and metastasis. TNBC is a heterogeneous disease comprising different molecular
subtypes including those with mesenchymal features. The tyrosine kinase AXL is expressed in
mesenchymal cells and plays a role in drug resistance, migration and metastasis. We confirm that
AXL is more expressed in mesenchymal TNBC cells compared to luminal breast cancer cells, and that
its invalidation impairs cell migration while having no or little effect on cell viability. Here, we found
that AXL controls directed migration. We observed that AXL displays a polarized localization at the
Golgi apparatus and the leading edge of migratory mesenchymal TNBC cells. AXL co-localizes with
F-actin at the front of the cells. In migratory polarized cells, the specific AXL inhibitor R428 displaces
AXL and F-actin from the leading edge to a lateral area localized between the front and the rear of
the cells where both are enriched in protrusions. In addition, R428 treatment disrupts the polarized
localization of the Golgi apparatus towards the leading edge in migratory cells. Immunohistochemical
analysis of aggressive chemo-resistant TNBC samples obtained before treatment reveals inter- and
intra-tumor heterogeneity of the percentage of AXL expressing tumor cells, and a preference of these
cells to be in contact with the stroma. Taken together, our study demonstrates that AXL controls
directed cell migration most likely by regulating cell polarity.
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1. Introduction
Triple negative breast cancer (TNBC) accounts for about 15% of breast cancers and is defined by
the lack of expression of estrogen receptor (ER) and progesterone receptor (PR), and the absence of
Her2 overexpression [1,2]. A pivotal challenge in the treatment of TNBC patients is their inter- and
intra-tumor heterogeneity [3–5]. TNBC encompasses a heterogeneous group including tumors with a
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mesenchymal phenotype [3,6,7]. TNBC is associated with poor prognosis, as a consequence of a high
rate of relapse and metastases following chemotherapy treatment [8–10].
The ability of some epithelial cells to acquire a mesenchymal phenotype is important during
development and wound healing [11–13]. This cellular plasticity, called epithelial-to-mesenchymal
transition (EMT), allowing the cells to gain new abilities to migrate and cross an extracellular matrix, is
crucial for the metastatic process [14–17]. In addition, cells undergoing EMT are less proliferative and
more prone to resist to chemo- and targeted-therapies [18–21].
AXL, first identified in chronic myelogenous leukemia patients [22], belongs along with TYRO3
and MERTK to the TAM family of receptor tyrosine kinases (RTK) [23]. Its name derives from the
Greek term “anexelekto”, which means uncontrolled. AXL can be activated by its ligand, the growth
arrest specific protein 6 (GAS6) [24,25] or through its interaction with other transmembrane receptors
such as human epidermal growth factor receptor 1 (EGFR) in TNBC [26]. AXL activation leads to
its autophosphorylation, switching on downstream signaling cascades such as PI3K/AKT, MAPK,
JAK/STAT, SRC and RHO pathways [27,28]. The involvement of AXL in EMT has been largely
documented [29–33], and it is likely through this property that AXL plays a role in migration, invasion,
drug resistance and metastases [28,29,34–45]. For these reasons, a large number of AXL inhibitors have
been developed [46]. So far, bemcentinib (R428) is the only inhibitor specific to AXL [47,48].
AXL has been proposed as a potential therapeutic target for breast cancers [29,30,47,49] and its
inhibition sensitizes cells to chemo- or targeted-therapies [36,38]. Among breast cancer cell lines, AXL
tends to be more expressed in TNBC, and more specifically in mesenchymal TNBC cells [38,50].
To our knowledge, there is no study describing the intracellular localization of AXL. By using
immunofluorescence, we have examined the intracellular localization of AXL and shown that AXL
displays a polarized localization in mesenchymal TNBC cells. AXL is present at the leading edge
and at the Golgi apparatus of migrating cells. AXL inhibition perturbs its polarized localization and
impairs directional migration. Altogether, these results provide novel insights about the implication of
AXL during the migration of mesenchymal cells.
2. Methods
2.1. Cell Lines, Cell Authentication and Cell Culture
Cell lines were purchased from the American Type Culture Collection (ATCC, LGC Promochem,
Molsheim, France) and authenticated (data not shown) by short tandem repeat profiling in 2018
using the PowerPlex® 16 System (Promega, Charbonnieres les bains, France; DC6531) [51]. Cells
lines were cultured as previously described [52–54]. Briefly, Hs578t and MDA-MB-157 cells were
cultured in DMEM (Thermo Fisher Scientific, Courtaboeuf, France; 31966047) supplemented with
10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin (P/S; Thermo Fisher
Scientific, Courtaboeuf, France; 10378016). BT-474 and MDA-MB-436 cells were maintained in
RPMI-1640 (Thermo Fisher Scientific, Courtaboeuf, France; 61870044) supplemented with 10% and
P/S. MDA-MB-231 cells were cultured in DMEM-F12 (Thermo Fisher Scientific, Courtaboeuf, France;
31331093) supplemented with 10% FBS and P/S. MCF7 cells were cultured in MEM (Sigma-Aldrich,
Saint-Quentin Fallavier, France; M2279) containing 10% FBS, 1.5 g/L sodium bicarbonate, 0.1 mM
non-essential amino acids (Thermo Fisher Scientific, Courtaboeuf, France; 11140050), 1 mM sodium
pyruvate and P/S. We maintained all cell lines at 37 ◦C in a humidified atmosphere with 5% CO2.
2.2. Protein Extraction
Cell lysates were obtained using a Laemmli buffer containing 50 mM Tris pH 6.8, 2% sodium
dodecyl sulfate, 5% glycerol, 2 mM 1,4-dithio-dl-threitol (DTT), 2.5 mM ethylene diaminetetraacetic
acid, 2.5 mM ethylene glycol tetraacetic acid, 2 mM sodium orthovanadate, 10 mM sodium fluoride, a
cocktail of protease (Roche, Meylan, France; 04693159001) and phosphatase (Thermo Fisher Scientific,
Courtaboeuf, France; 1861277) inhibitors, and boiled at 100 ◦C for 10 min. Protein concentration was
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calculated using the reducing agent-compatible version of the BCA Protein Assay kit (Thermo Fisher
Scientific, Courtaboeuf, France; 23252).
2.3. Immunoblot
Proteins were fractionated by SDS-PAGE under reducing conditions (4–15% TGX gels, BioRad,
Marnes la Coquette, France; 456-8053) and blotted onto nitrocellulose membranes (BioRad, Marnes
la Coquette, France; 1704159). The membranes were blocked with 5% BSA in TBS containing 0.1%
Tween20 (TBS-T) and hybridized with the primary antibody of interest overnight at 4 ◦C. Then,
the membranes were washed in TBS-T and hybridized with the secondary antibody for 1 h at room
temperature. Antibodies were diluted in TBS-T containing 5% BSA. After washes, immune complexes
were revealed by chemiluminescence (Thermo Fisher Scientific, Courtaboeuf, France; 34580), imaged
using the ChemiDoc™ Imaging Systems (BioRad, Marnes la Coquette, France) and analyzed with the
Image Lab Software (BioRad, Marnes la Coquette, France).
2.4. Small Interfering RNAs (siRNAs) and Transfection
Cells were seeded into six well-plates (TPP, Trasadingen, Switzerland; 92106) and next day,
transfection was performed with 20 nM small interfering RNAs (siRNA) using INTERFERin reagent
(Polyplus, Ozyme, Saint Quentin en Yveline, France; 409-50) in Opti-MEM medium (Thermo
Fisher Scientific, Courtaboeuf, France; 31985070), according to the manufacturers’ instructions.
For immunofluorescence, cells were plated one day post transfection on a coverslip for 2 days before
fixation. The siRNAs used were as follows: Allstars negative control (Qiagen, Courtaboeuf, France;
SI03650318), AXL#9 (Qiagen, Courtaboeuf, France; SI00605304) and AXL#10 (Qiagen, Courtaboeuf,
France; SI00605311).
2.5. Random Migration
Hs578t and MDAMB231 cells were plated in a 24 well plate (TPP, Trasadingen, Switzerland; 92424).
Imaging was started one hour following treatment with DMSO or R428 (Sellekchem, Euromedex,
Mundolsheim, France; S2841), or 3 days after siRNA transfection. One image every 20 min were
acquired using transmitted light for 6 h using IncuCyte® ZOOM Live-Cell Analysis System. Individual
cells were manually tracked with the ImageJ plugin Manual Tracking. Directionality was calculated
with the ImageJ plugin Chemotaxis and migration tool.
2.6. Cell Survival Assays
Cell survival was assessed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega,
Charbonnieres les bains, France; G7570) according to the manufacturer’s instructions. Briefly, a volume
of CellTiter-Glo reagent medium was added (v/v). The plates were mixed and incubated 10 min at
room temperature. Then luminescence was monitored using Tecan Infinite 200.
2.7. Immunoprecipitation (IP)
Cells were cultured with serum prior to treatment with R428 or serum-starved prior to stimulation
with Gas6. Cells were lysed in a cold lysis buffer (100 mM NaCl, 50 mM Tris-HCl, pH 7.4, 1 mM EDTA,
1 mM EGTA, 1% NP40, 10% glycerol, DTT 1M and protease and phosphatase inhibitors) under rotation
for one hour at 4 ◦C. The cellular debris were removed by centrifugation at 13,000 rpm for 10 min at
4 ◦C. 1 µg of AXL-goat antibody or 1 µg of Goat IgG (negative control) were incubated with 1 mg
of protein lysate overnight at 4 ◦C with rotation. Protein G-coupled beads (Thermo Fisher Scientific,
Courtaboeuf, France; 20398) were then added for 1 h incubation under rotation at 4 ◦C. Beads were
washed four times with cold lysis buffer before extraction with Laemmli buffer for 10 min at 100 ◦C.
Immunoprecipitated proteins were separated by SDS-PAGE as indicated in the immunoblot section
(See above).
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2.8. Immunofluorescence (IF)
Samples were washed in PBS and fixed in 4% PFA for 15 min. Permeabilization was performed in
PBS supplemented with 0.2% BSA and 0.05% saponin for 10 min. Primary antibodies were incubated
overnight at 4 ◦C in a humidified chamber. After 3 washes of 5 min in TBS Tween 0.05%, secondary
antibodies and DAPI (1 µg/mL) were incubated one hour at room temperature. Slides were mounted
using VectaMount (Vector Laboratories, Eurobio Scientific, Les Ulis, France; H5501). Acquisitions were
done using an epifluorescence microscope Leica DM6000B and analyzed using ImageJ.
2.9. Wound Assays
Cells were grown on glass coverslips (Marienfeld, VWR, Fontenai-sous-Bois, France; 01115220)
in culture-insert 2 well (Ibidi, CliniSciences, Nanterre, France; 80209). Once confluency was reached,
cells were treated with DMSO or R428 for one hour before removing the insert to allow the cells to
migrate, and starved or stimulated with Gas6 (R&D systems, Lille, France; 885GSB) at 400 ng/mL. To
analyze Golgi orientation, cells were fixed after 4 h of migration and immunostained with anti-GM130
antibody and DAPI to visualize the Golgi and the nucleus. Cells were scored as polarized when the
Golgi was found facing towards the wound.
2.10. AXL Localization Analysis
Cells were plated on coverslip for 3 days and then treated with DMSO (CTRL) or R428 (0.5, 1 or
2 µM), Ly294002 (10 µM, Sellekchem, Euromedex, Mundolsheim, France; S1105), NSC-23766 (50 µM,
Tocris, Bio-Techne SAS, Noyal Châtillon sur Seiche, France; 2161), PP2 (10 µM, Sellekchem, Euromedex,
Mundolsheim, France; S7008), Dasatinib (10 µM, Sellekchem, Euromedex, Mundolsheim, France;
S1021) and Brefeldin A (10 µg/mL, Sellekchem, Euromedex, Mundolsheim, France; S7046). Treatments
were performed during 2 h, or 30 min for the Brefeldin A and 30 min, 1-, 2- and 4-h for the R428.
2.11. Patient Samples and Multiplexed Immunohistochemistry (IHC)
Core biopsy samples from a series of TNBC patients who underwent neoadjuvant treatment at
Institut Curie were retrieved from the archives of the Pathology Department (Table S1). Cases were
selected based on the presence of residual disease following neoadjuvant treatment, thus representing
chemo-resistant TNBC (Table S1). Experiments were performed in accordance with Bioethics Law No.
2004-800 and the Ethics Charter of the French National Cancer Institute (INCa), with the approval of
the ethics committee of our institution. Informed consent was not required. The women were informed
of the use of their tissues for research and did not oppose this research.
Three-micron thick serial sections were cut for subsequent immunophenotypical analyses that
were performed on a Leica Bond RX Automated IHC stainer. Slides were first dewaxed using Bond
Dewax solution (Leica Biosystems, Newcastle, UK; AR9222). Next, we used HIER1 (pH = 6) solution
(Leica Biosystems, Newcastle, UK; AR9961) to perform heat induced epitope retrieval. Endogenous
peroxidases were blocked using REAL Peroxidase-Blocking solution (Dako France, Agilent, Les Ulis,
France; S2023) for 10 min followed by incubation with Protein Block Serum-Free solution (Dako France,
Agilent, Les Ulis, France; X0909) for 10 min. Multiplex was done using Opal 7-Color Automation
IHC Kit (PerkinElmer, Courtaboeuf, France; NEL821001KT). Primary antibody against AXL was used
at 1/300 and was incubated for 1 h at room temperature followed by OpalTM Polymer HRP and
Opal620 Reagent according to manufacturer instructions. Then, we used HIER1 (pH = 6) solution
to remove antibodies construction (15 min, 95 ◦C) and we performed the second step of multiplex
with pan-keratin AE1/AE3 antibody (1/500, 45 min, 24 ◦C) revealed by Opal650 Reagent. Images were
acquired on a Vectra3 from PerkinElmer. We used InForm software (PerkinElmer, Courtaboeuf, France)
to distinguish stroma from tumor areas based on keratin positivity signal and AXL intensity was
measured in tumor cells. Analysis of cell in contact with the stroma was done using ImageJ.
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2.12. Antibodies and Staining
AXL (IHC-IF, Cell Signaling, Ozyme, Saint-cyr-l’école, France; 8661), AXL (IF-IP, R&D systems,
Lille, France; AF154), AXL (WB, Cell Signaling, Ozyme, Saint-cyr-l’école, France; 4939), Vimentin (BD
Biosciences, Le pont de claix, France; 550513), E-cadherin (BD Biosciences, Le pont de claix, France;
610181), GAPDH (Cell Signaling, Ozyme, Saint-cyr-l’école, France; 2118), Phalloidin (Thermo Fisher
Scientific, Courtaboeuf, France; R37112), GM130 (R&D systems, Lille, France; NBP1-89757), LAMP1
(Cell Signaling, Ozyme, Saint-cyr-l’école, France; 9091T), pan-keratin AE1/AE3 (Dako France, Agilent,
Les Ulis, France; M3515), (Cell Signaling, Ozyme, Saint-cyr-l’école, France; 9491) and anti-goat IgG
(Sigma-Aldrich, Saint-Quentin Fallavier, France; SAB3700257).
2.13. Statistics
Significance was tested with unpaired two-tailed Student’s t-test using GraphPad Prism (GraphPad,
San Diego, CA, USA). The method used, p values and n numbers are indicated in the figure legends.
p values of significance are represented as *** p < 0.001, ** p < 0.01 and * p < 0.05. The exact value is
indicated when possible. All graphs represent mean ± s.d.
3. Results
3.1. AXL Controls Directed Migration in Mesenchymal TNBC Cell Lines
We assessed AXL expression by western-blot in five mesenchymal TNBC cell lines (BT549,
MDA-MB-436, MDA-MB-231, MDA-MB-157 and Hs578t) as well as in one ER-positive/HER2-positive
(BT474) and one ER-positive/HER2-negative (MCF7) epithelial luminal cell lines. As expected,
the mesenchymal cell lines express Vimentin (a mesenchymal marker) and no/low E-cadherin (an
epithelial marker), in contrast to the luminal epithelial cells (Figure S1A in Supplementary Materials).
We found that AXL is more expressed in mesenchymal TNBC cells compared to the two luminal cell
lines (Figure S1A) confirming previous studies [38]. MDA-MB-231 and Hs578t cells, which display the
highest levels of AXL, were chosen for further analyses (Figure S1A). By using two distinct siRNA
targeting AXL (Figure 1A), we found that AXL depletion in MDA-MB-231 and Hs578t cell lines impairs
cell motility (Figure S1B) but not cell viability/proliferation (Figure S1C), in agreement with published
data [33,47,49,55–58]. We next investigated whether AXL invalidation affects directed (or oriented) cell
migration (Figure 1B). The depletion of AXL in Hs578t (Figure 1C) and MDA-MB-231 (Figure S1D) cells
decreased the directionality of cell migration. We next investigated whether the kinase activity of AXL
was required for cell migration directionality. First, we confirmed that specific inhibition of AXL, using
the small molecule R428, impairs basal AXL tyrosine phosphorylation (Figure 1D and Figure S1E)
and cell motility (Figure S1F) in a dose dependent manner in our cellular models. Similarly to AXL
depletion (Figure 1C and Figure S1D), AXL inhibition disturbed the directionality of cell migration of
Hs578t (Figure 1E,F) and MDA-MB-231 cells (Figure S1G).
Taken together, our results confirmed that AXL invalidation impairs cell motility. Most importantly,
we found that AXL controlled directed migration.
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Figure 1. AXL controls directed cell migration. (A) AXL protein expression by western blotting in 
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the method used to measure cell directionality. (C) Evaluation of the directionality of Hs578t cells 
three days after transfection with CTRL, AXL9 or AXL10 siRNA obtained from 110, 100 and 113 
cells in three independent experiments, respectively. (** p = 0.003; 0.007). (D) Hs578t cells were 
cultured with serum and treated with DMSO (CTRL) or various concentrations (0.25, 0.5, 1 or 2 µM) 
of R428 for 6 h. Basal phosphorylated active AXL was then detected by western blotting using an 
anti-phosphotyrosine antibody after AXL immunoprecipitation. As a negative control, IgG instead 
of AXL antibodies were used with cells treated with DMSO. (E) Representative migration 
trajectories of Hs578t cells treated with DMSO (CTRL) or various concentrations (1 or 2 µM) of R428 
for 6 h. (F) Directionality of Hs578t cells treated with DMSO (CTRL) or various concentrations (0.5, 1 
or 2 µM) of R428 obtained from 108, 96, 80 and 75 cells in three independent experiments, 
respectively. (ns > 0.05, * p = 0.012; 0.024). All graphs represent means and small bars indicate 
standard deviation. 
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2C–E) and MDA-MB-231 (Figure S2B) cells. 
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interfering RNAs (siRNA). GAPDH was used as loading control. (B) Schematic representation of the
method used to measur cell directionality. (C) Evaluation of the directionality of Hs578t cells three
days after transfection with CTRL, AXL9 or AXL10 siRNA obtained from 110, 100 and 113 cells in
three independent experiments, respectively. (** p = 0.003; 0.007). (D) Hs578t cells were cultured ith
serum and treated with DMSO (CTRL) or various concentrations (0.25, 0.5, 1 or 2 µM) of R428 for 6 h.
Basal phosphorylated active AXL was then detected by western blotting using an anti-phosphotyrosine
antibody after AXL immunoprecipitation. As a negative control, IgG instead of AXL antibodies were
used with cells treated with DMSO. (E) Representative migration trajectories of Hs578t cells treated
with DMSO (CTRL) or various concentrations (1 or 2 µM) of R428 for 6 h. (F) Directionality of Hs578t
cells treated with DMSO (CTRL) or various concentrations (0.5, 1 or 2 µM) of R428 obtained from 108,
96, 80 and 75 cells in three independent experiments, respectively. (ns > 0.05, * p = 0.012; 0.024). All
graphs represent means and small bars indicate standard deviation.
3.2. Polarized Localization of AXL at the Leading Edge and the Golgi Apparatus in Migrating Cells
In order to better understand how AXL regulates cell migration and its directionality, we then
analyzed its localization by immunofluorescence in mesenchymal TNBC cell lines. First, we validated
two different AXL antibodies (AF154 ab and C89E7 ab) for immunofluorescence staining in Hs578t
cells depleted or not for AXL (Figure S2A). Both antibodies gave similar results with a perinuclear
and a plasma membrane enriched localization of AXL, which decreased in AXL depleted Hs578t cells
(Figure S2A). Further experiments were then performed using the AXL AF154 ab, which gave stronger
signals. We observed that AXL localization at the plasma membrane depended on the polarized state
of Hs578t cells (Figure 2A). Indeed, AXL was undetectable or present all around the plasma membrane
in non-polarized cells whereas it displayed enrichment at a specific region resembling to a leading edge
when the cells were polarized (Figure 2A,B). To confirm the presence of AXL at the front of migratory
cells, a wound healing experiment was performed revealing that AXL is indeed enriched at the leading
edge of migrating Hs578t (Figure 2C–E) and MDA-MB-231 (Figure S2B) cells.
To better characterize the AXL perinuclear localization (Figure S2A), we performed a co-staining
experiment using antibodies against AXL and GM130, a cis-Golgi marker, and we demonstrated
that AXL was enriched at the Golgi apparatus (Figure 2F). The treatment of cells with Brefeldin A,
which causes the disruption of the Golgi apparatus, led to the loss of AXL at the perinuclear region
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(Figure S2C). Moreover, we noticed an enrichment of AXL in structures between the cell front and the
Golgi apparatus (Figure 2E), which were positives for Lamp1 (Figure S2D), suggesting that AXL was
present in vesicles between these two compartments (Figure 2G).
Taken together, our results highlighted a polarized localization of AXL at the leading edge and at
the Golgi apparatus in migratory cells.
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independent experiments. (*** p < 0.001). (C) Upper panel: schematic representation of a wound 
healing experiment. Lower panel: AXL staining (green) in Hs578t cells six hours after wound 
healing. Arrows point to AXL enrichment at the front of migrating cells. (D) Linescan of AXL 
intensity (grey value) of Hs578t cells (following the dashed red arrow on the top image). (E) AXL 
intensity at the lateral area and at the rear of Hs578t cells relative to the front obtained from 42 cells 
in four independent experiments. (** p = 0.008; 0.0011). Arrowheads in inset point to AXL-stained 
structures. (F) AXL (green) and GM130 (red) staining of Hs578t cells. Arrowheads point to AXL 
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3.3. The Inhibition of AXL Disrupts Its Localization at the Leading Edge of Migrating Cells
Next, we explored the consequences of AXL inhibition on its polarized localization in migrating
cells. R428 treatment induces the loss of AXL staining at the front of migrating cells at different
doses (Figure 3A and Figure S3A) and in a time (Figure 3B and Figure S3B) dependent manner. This
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phenomenon was accompanied by a relocation of AXL to a lateral area between the leading edge
and the rear of the polarized migrating cells (Figure 3A,B and Figure S3C–E). The inhibition of AXL
downstream effectors such as the PI3K/AKT-Rac1 pathway or SRC kinases did not induce a relocation
of AXL at the lateral area in migratory cells (Figure S3F,G).
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3.4. AXL Inhibition Disrupts Actin Polymerization at the Leading Edge of Migrating Cells
We observed that AXL co-localizes with actin filaments at the leading edge of migrating cells
(Figure 4A,B). As the activation of the small-GTPase protein Rac, acting downstream of AXL,
regulates actin polymerization [28,37,59], we next investigated whether AXL invalidation affects
actin polymerization in migrating cells. We found that the depletion (Figure S4) or the inhibition
(Figure 4C) of AXL significantly reduced the intensity of actin staining at the leading edge of migratory
cells. R428 at a dose of 0.5µM was sufficient to obtain the maximal decrease of actin polymerization at the
front of the cells presenting an enrichment of AXL at the lateral area (Figure 4C). Upon AXL inhibition,
F-actin became enriched at the lateral area where AXL relocated following its inhibition (Figure 4D–F).
At this specific site, we observed protrusions enriched for both AXL and actin (Figure 4G,H).
Our data show that AXL and F-actin co-localized at the leading edge of migratory cells and that
AXL participates in actin polymerization at the front.
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Arrowheads point to protrusions. Scale bars, 20 µm unless otherwise specified. All graphs represent
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3.5. AXL Controls the Polarized Position of the Golgi Apparatus during Migration
The polarized position of the Golgi apparatus, facing the front of migration, has been shown to be
crucial in directed migration [60]. We therefore examined whether AXL activity controls the position
of the Golgi apparatus in a wound healing experiment. First, we confirmed that AXL was localized at
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the leading edge of the migrating cells (Figure 2C), facing the wound, in untreated cells and not in
R428-treated cells (Figure 5A). Then, we analyzed the position of the Golgi apparatus; the cells being
considered polarized when the Golgi apparatus was facing the wound. We found that the cells treated
with R428 were less polarized (Figure 5B). Conversely, the incubation of cells with Gas6, which induced
AXL phosphorylation (Figure 5C), increased significantly the number of polarized cells (Figure 5B).
Altogether, we show that AXL contribute to the polarized position of the Golgi apparatus
during migration.
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Figure 5. AXL regulates the polarized pos tion of the Golgi a paratus during directed migration.
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healing (4 h). The ce ls ere st i , ( reen) and GM130 (Red). Ar owheads point o
AXL enrichment in polarized cell. (B) Left panel: rep sentative images of Hs578t cells trea ed with
DMSO (CTRL) or 2 µM R428 (R428) or starved (Starved) and then stimulated with 400 ng/mL of Gas6
(Gas6) obt ined from 350, 264, 280, 199 and 207 cells in thre independ nt ex riments, respectively.
The cells were stained for DAPI and GM130. Arrowheads show a polarized Golgi (towar s t the
woun ), crosses show unpolarized Golgi. Right panel: Quantification of cells possessing a polarized
Golgi relative to the CTRL condition. The graph represents means and small bars indicate standard
deviation (* p = 0.021; 0.022; 0.039). (C) Gas6 leads to AXL activation. Hs578t cells were starved and
then stimulated with 400 ng/mL of Gas6 for 30 min. Phosphorylated active AXL was then detected by
western blotting using an anti-phosphotyrosine antibody after AXL immunoprecipitation (as a negative
control, IgG instead of AXL antibodies were used with cells treated with DMSO). Scale bars, 20 µm.
3.6. AXL-Expressing Tumor Cells Are Preferentially Located in Contact with the Stroma in Human TNBC
We e amined the expression of AXL at he protein level in 31 human TNBC samples obtained from
patients before receiving neoadjuvant treatment. These patients did not reach pathologic complete
response after chemotherapies; hence we focused on a cohort of chemo-resistant TNBC (Table S1). We
performed a multiplexed IHC experiment using AXL and pan-keratin antibodies. Keratin staining
allowed us to discriminate cancer cells (keratin-positive) from the stroma (keratin-negative) and to
explore the proximity of the cancer cells to the tumor microenvironment (Figure 6A,B). We observed a
high heterogeneity of AXL staining in these samples (Figure 6A,B). Within a tumor, not all the tumor
cells expressed AXL, showing intra-tumor heterogeneity of AXL staining. Importantly, we found that
the majority of the AXL-expressing cells (>50%) were in contact with the stroma in 58% of our 31 TNBC
samples (Figure 6A,B).
These data highlight inter- and intra-tumor heterogeneity of AXL expression as well as a preferential
localization of AXL-positive tumor cells at the proximity of the stroma in therapy-naïve TNBC samples
with clinically proven features of chemo-resistance.
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4. Discussion
TNBC is the breast cancer subtype associated with the worst prognosis due to high percentage of
relapse and metastases following treatment. TNBC encompasses a heterogeneous group including
tumors with a mesenchymal phenotype [3,6]. EMT is a crucial process during normal development
and contributes to invasion and the formation of metastases in human tumors [11–17,37,61,62].
AXL is a protein kinase modulating EMT, which is involved in cell invasion and resistance to
therapies [23,28,31,32,37,63,64].
We focused our study on mesenchymal TNBC cells and found that they express higher levels
of AXL compared to luminal cells as previously reported [38,49,65,66]. The expression of AXL was
variable among the mesenchymal TNBC cell lines, some expressing low levels (BT549, MDA-MB-157
and MDA-MB-436), and some expressing high levels (MDA-MB-231 and Hs578T), in agreement
with previous reports [38,49,67,68]. We found that AXL invalidation had little/no effect on cell
viability/proliferation but impairs cell migration speed, as previously shown [33,47,49,55–58]. These
results were also in concordance with an in vivo study showing that AXL is not involved in tumor
growth but regulates the dissemination of cancer cells and the development of metastases [69].
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In this study, we further characterized the function of AXL in migration and we provided
evidence that AXL controls directed migration. Indeed, its depletion or its inhibition impaired the
directionality of the two studied mesenchymal TNBC cell lines (MDA-MB-231 and Hs578T). Using
a cell biology approach, we then tried to understand by which molecular mechanisms AXL could
affect directed migration. Mainly due to poor quality antibodies that are commercially available
for immunofluorescence analyses, very few studies have addressed the intracellular localization of
AXL [33]. Here, using two different validated anti-AXL antibodies, we show that AXL had a polarized
localization in migrating mesenchymal TNBC cells being mainly present at the leading edge and at
the Golgi apparatus. Although its localization at the front was not surprising due to its established
function in migration and invasion, its localization at the Golgi apparatus was more unexpected.
To our knowledge, the presence of AXL at the lamellipodia of breast cancer polarized cells toward
the scratch wound has been documented only in MDA-MB-231 cells [33]. Another study indicates that
the protrusions, which are induced when MDA-MB-231 cells are stimulated by EGF, are reduced when
the cells are depleted for AXL [26].
This is the first time that AXL is described to be localized at the Golgi apparatus. Although not
discussed by the authors, a perinuclear AXL staining has been observed in migratory MCF10A cells [33].
Interestingly, we observed AXL positive-vesicles between the Golgi apparatus and the migrating front,
suggesting a trafficking of AXL between these two compartments. It is possible that AXL is specifically
transported to the leading edge of migratory cells via these vesicles. Moreover, once activated, AXL
could be endocytosed to the Golgi apparatus before recycling as shown for other transmembrane
receptors such as EGFR [70]. These hypotheses could be verified by live-imaging with cells expressing
ectopically a fluorescent-tagged AXL. Noteworthy, AXL has been shown recently to mediate the
anterograde trafficking of lysosomes (Lamp1-positive vesicles) in esophageal adenocarcinoma cells [58],
regulating the secretion of cathepsin B [58], which is involved in matrix degradation and invasion [71,72].
Altogether, these results suggest that AXL may regulate migration and invasion by controlling vesicle
trafficking. Further experiments are required to decipher the molecular mechanisms by which AXL
acts on membrane trafficking.
Directed migration of mesenchymal cells involves polarized and dynamic architecture of the actin
cytoskeleton [60]. We observed that AXL colocalizes with F-actin at the leading edge of migrating
cells. The inhibition of AXL with the specific inhibitor R428 decreases F-actin intensity at the front of
migrating cells suggesting that AXL controls actin polymerization at that site. We did not observe
a complete decrease of actin polymerization at the front upon Axl inhibition suggesting that actin
polymerization did not rely solely on Axl activity. Interestingly, AXL inhibition displaced AXL in
migrating cells from the leading edge to a lateral area localized between the front and the rear of
the cells. This suggests that the kinase activity of AXL was required for its presence at the leading
edge during migration. Following treatment with R428, F-actin became enriched at the specific lateral
area where AXL was mislocalized. The kinase activity of AXL was not by itself required for F-actin
polymerization because F-actin polymerization was still stimulated at the lateral area of R428-treated
cells where AXL relocalizes.
We also reported that AXL inhibition affected the polarized location of the Golgi apparatus in
a wound healing assay, indicating that AXL activity was required for this process. The molecular
mechanisms by which AXL controls the polarity of the Golgi apparatus could be possibly though the
phosphorylation of specific substrates at and/or close to the Golgi as shown for polarity proteins such
as Par6α [73].
The presence of filaments (or membrane extensions) containing both AXL and F-actin observed
upon AXL inhibition at the lateral side of the migrating cells, could also explain why AXL inhibition
disrupts directed migration. Regarding protrusions, it has been recently shown that AXL invalidation
enhances invadopodia formation in melanoma cells [74]. Many studies have reported a role for AXL in
invasion in various cellular models, including breast cancer cells [23,28,31,64], but whether it occurs
through controlling invadopodia formation remains to be investigated.
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We explored the localization of AXL in our cohort of chemo-resistant TNBC obtained before
neoadjuvant treatment. In these samples, we detected both inter- and intra-tumor heterogeneity
regarding the number of tumor cells expressing AXL. We also observed that AXL was mainly expressed
by tumor cells in contact with the stroma. A recent study shows that AXL expression is higher in
collagen-I rich microenvironment [75] suggesting that the extracellular matrix could have an impact
in AXL expression. In breast tumors, Gas6 is highly expressed in pre-invasive lesions associated
with increased infiltrating macrophages [76]. Gas6 produced by macrophages is essential for the
transition of premalignant to invasive breast cancer [76]. Another study shows that AXL-expressing
TNBC cells can polarize macrophages towards an activated phenotype producing pro-tumorigenic
chemokines and cytokines [66]. The authors further show that AXL inhibition decreases the activity
of these activated macrophages reducing cancer cell invasiveness and restoring drug sensitivity of
cancer cells [66]. Cancer-associated fibroblasts can also produce Gas6 following therapy leading to the
migration of AXL-positive lung cancer cells [77]. Collectively, the contact with extracellular matrix
may lead to AXL overexpression in cancer cells and Gas6, secreted by some stromal cells, could induce
the polarization of the Golgi toward the microenvironment allowing the escape of tumor cells.
In conclusion, we found that AXL is polarized in migrating cells and that AXL plays a role in
directed migration most likely by controlling the localization of AXL and F-actin at the leading edge
and Golgi apparatus polarization. AXL could be a powerful actor of the ability of cancer cells to escape
the tumor core through its expression in cells at the contact with the stroma and its stimulation by
Gas6 secreted in the tumor microenvironment.
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Abbreviations
AXL AXL receptor tyrosine kinase
DMSO Dimethyl Sulfoxide
DTT 1:4-dithio-dl-threitol
EGFR Epidermal Growth Factor Receptor 1
EMT Epithelial-to-Mesenchymal Transition
ER Estrogen Receptor
F-actin Filament of actin
FBS Fetal Bovine Serum
GAS6 Growth Arrest Specific protein 6
IHC Immunohistochemistry
INCa French National Cancer Institute
IF Immunofluorescence
IP Immunoprecipitation
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Lamp1 Lysosomal Associated Membrane Protein 1
MERTK MER receptor Tyrosine Kinase
PR Progesterone Receptor
P/S Penicillin and streptomycin
Rac Rac family of small GTPases
RTK Receptor Tyrosine Kinases
TNBC Triple Negative Breast Cancer
TYRO3 TYRO3 receptor tyrosine kinase
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